Literature DB >> 12112396

Preferential action of gabapentin and pregabalin at P/Q-type voltage-sensitive calcium channels: inhibition of K+-evoked [3H]-norepinephrine release from rat neocortical slices.

David J Dooley1, Cindy M Donovan, Wolfgang P Meder, Steven Z Whetzel.   

Abstract

Gabapentin (GBP; Neurontin) and pregabalin (PGB; CI-1008), efficacious drugs in several neurological and psychiatric disorders, inhibit neurotransmitter release from mammalian brain slices at therapeutically relevant concentrations. A detailed investigation, exploring the basis for this in vitro phenomenon, focused on norepinephrine (NE) and rat neocortical tissue in complementary assays of neurotransmitter release and radioligand binding. The results are consistent with the hypothesis that GBP, PGB, and related substances decrease neocortical NE release by acting at the alpha2delta subunit of presynaptic P/Q-type voltage-sensitive Ca2+ channels (VSCC) subserving Ca2+ influx in noradrenergic terminals. The inhibitory action appears competitive with [Ca2+]o and preferential to those neurons undergoing prolonged depolarization. Other results indicate that the reduction of exocytotic NE release is independent of L- and N-type VSCC, classical drug/peptide binding sites on VSCC, Na+ channels, alpha2-adrenoceptors, NE transporter, and system L amino acid transporter. These findings suggest a selective modulation of P/Q-type VSCC that are implicated in neurotransmission and several GBP-responsive pathologies. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12112396     DOI: 10.1002/syn.10094

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  37 in total

Review 1.  P/Q-type calcium channel modulators.

Authors:  V Nimmrich; G Gross
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

2.  New Horizons in the development of antiepileptic drugs: Innovative strategies.

Authors:  Wolfgang Löscher; Dieter Schmidt
Journal:  Epilepsy Res       Date:  2006-06       Impact factor: 3.045

Review 3.  Pregabalin: in the treatment of postherpetic neuralgia.

Authors:  James E Frampton; Rachel H Foster
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Is early postoperative administration of pregabalin beneficial for patients with lung cancer?-randomized control trial.

Authors:  Takuro Miyazaki; Tetsuya Sakai; Shuntaro Sato; Naoya Yamasaki; Tomoshi Tsuchiya; Keitaro Matsumoto; Ryotaro Kamohara; Go Hatachi; Ryoichiro Doi; Takeshi Nagayasu
Journal:  J Thorac Dis       Date:  2016-12       Impact factor: 2.895

5.  Chest tube insertion is one important factor leading to intercostal nerve impairment in thoracic surgery.

Authors:  Takuro Miyazaki; Tetsuya Sakai; Naoya Yamasaki; Tomoshi Tsuchiya; Keitaro Matsumoto; Tsutomu Tagawa; Go Hatachi; Koichi Tomoshige; Mariko Mine; Takeshi Nagayasu
Journal:  Gen Thorac Cardiovasc Surg       Date:  2013-10-06

6.  Significant improvement of chronic pain by Pregabalin after thoracotomy: report of four cases.

Authors:  Noriyuki Matsutani; Masafumi Kawamura
Journal:  Surg Today       Date:  2012-08-05       Impact factor: 2.549

Review 7.  Pregabalin: as adjunctive treatment of partial seizures.

Authors:  Greg Warner; David P Figgitt
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 8.  Pregabalin: in the treatment of postherpetic neuralgia.

Authors:  Kate McKeage; Susan J Keam
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

9.  Pregabalin for the management of partial epilepsy.

Authors:  Philippe Ryvlin; Emilio Perucca; Sylvain Rheims
Journal:  Neuropsychiatr Dis Treat       Date:  2008-12       Impact factor: 2.570

10.  Pregabalin in the management of partial epilepsy.

Authors:  Amir M Arain
Journal:  Neuropsychiatr Dis Treat       Date:  2009-08-20       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.